Lastly, patients with heart failure (HF), composite cardiovascular events (i.e., unstable angina, ischemic heart disease, myocardial infarction, coronary stenting, percutaneous coronary intervention (PCI), coronary artery bypass), and clinically significant portal hypertension events (i.e., esophageal varices with and without bleeding, ascites, hepatic failure, hepatorenal syndrome, portal hypertension, liver transplant status, fibrosis, sclerosis and cirrhosis of the liver, hepatic encephalopathy, jaundice) were excluded if they occurred before inclusion to the cohort or prior to the index event
Tedesco, Antonio C
doi: 10.1007/s12011-014-0128-z 252 dos Santos RochaPBde Castro AmorimAde SousaAFdo MonteSJda Mata SousaLCdo Nascimento NogueiraNet al
GLP-1/GIP Injectable Options - Semaglutide (Ozempic, Wegovy) starts at $200/mo - Tirzepatide (Mounjaro, ZepBound) starts at $299/mo - Dulaglutide (Trulicity) (Rx only) - Liraglutide (Victoza, Saxxenda) (Rx only) - Lixisenatide (Adlyxin) (Rx only) - Retatrutide (Currently illegal to dispense, but will be available when FDA moves it from Category 2 sometime in 2026
Patients with type 2 diabetes may experience low blood glucose levels if taking semaglutide alongside other medications to lower blood sugar, such as insulin
